Eprodisate Sodium

N/A

Report date: 2023/04/25 13:50:49
NME

Base Information

Drug NameEprodisate Sodium
Drug Alias Name依罗沙特Eprodisato伊罗地塞Fibrillex伊罗地塞钠 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerum amyloid A protein inhibitors
TargetsSerum amyloid A protein
Therapy Area/IndicationsAmyloidosisMetabolic SyndromeDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[24] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBellus Health Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAuven TherapeuticsC.T. Development America IncBellus Health Inc
Active IndicationsN/A
Inactive IndicationsAmyloidosisMetabolic SyndromeDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksKEGG